- Free from Publisher P Spallarossa, M Schiavo, P Rossettin, S … - Diabetes Care, 2001 - Am Diabetes Assoc OBJECTIVE—Sulfonylureas block the activation of vascular potassium-dependent
ATP channels and impair the vasodilating response to ischemia in nondiabetic
individuals, but it is not known whether this occurs in type 2 diabetic ... Cited by 16 - Related articles - BL Direct - All 6 versions
EJ Abbink, P Pickkers, AJ Van Rosendaal, JA … - Diabetic Medicine, 2002 - interscience.wiley.com MethodsTwo groups of 12 Type 2 diabetes mellitus patients participated in a
double-blind randomized cross-over study consisting of two 8-week periods, in
which treatment with orally administered glibenclamide (15 mg/day) was ... Cited by 26 - Related articles - BL Direct - All 3 versions
VM Montori, SF Dinneen - Evidence-based Diabetes Care: editors Hertzel C. …, 2001 - books.google.com CHAPTER 15 Currently Available Oral Hypoglycemic Agents for Type 2 Diabetes
Mellitus Victor M. Montori, MD, and Sean F. Dinneen, MD, FRCPI, FACP ABSTRACT
When lifestyle modification fails to maintain adequate glycemic control in ... Cited by 5 - Related articles - All 2 versions
[CITATION] Different effects of glibenclamide and gliclazide on forearm vascular reserve in type-2 …
RB Haynes, HC Gerstein - Evidence-based Diabetes Care: editors Hertzel C. …, 2001 - books.google.com EVIDENCE CHAPTER 1 What Evidence? R. Brian Haynes, MD, PhD, FRCPC, FACP, and
Hertzel C. Gerstein, MD, MSc, FRCPC ABSTRACT The term" evidence-based medicine"
refers to the explicit, conscientious, and judicious use of current best ... Cited by 7 - Related articles - All 2 versions
WS Aronow, C Ahn - The American journal of cardiology, 2001 - Elsevier Two hundred five men and 431 women (mean age 80 ± 9 years; range 60 to 100)
with diabetes mellitus and prior MI were followed in a long-term health care
facility for the incidence of new coronary events. Patients were considered ... Cited by 22 - Related articles - BL Direct - All 7 versions
A Halkin MD, A Roth MD, M Jonas MD, S … - Journal of thrombosis and thrombolysis, 2001 - Springer Amir Halkin MD,* Arie Roth MD,* Michael Jonas MD,{ Solomon Behar MD{ *
Department of Cardiology, Tel-Aviv Sourasky Medical Center, and { Neufeld
Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel. On ... Cited by 25 - Related articles - BL Direct - All 4 versions
- ►bmj.com T Reffelmann, HG Klues, P Hanrath, ER … - British Medical Journal, 2002 - heart.bmj.com Results: One hour after glibenclamide, serum insulin increased from (mean (SD))
7.4 (2.0) to 44.8 (25.5) mU/l (p < 0.005), and C peptide from 1.4 (0.4) to 3.4
(1.2) ng/l (p = 0.005). In normal coronary arteries coronary flow reserve ... Cited by 12 - Related articles - BL Direct - All 7 versions
- ►cardiovascres.org HF del Valle, EC Lascano, JA Negroni, AJ … - Cardiovascular research, 2001 - cardiovascres.org Two types of K-ATP channel modulators have been used in patients. K-ATP channel
openers (eg pinacidil and nicorandil) have been proposed in the treatment of
hypertension and angina pectoris [6,7], while K-ATP channel blocking ... Cited by 24 - Related articles - All 8 versions
- ►di-em.de [PDF] P Fasching - Diabetologia, 1998 - Springer Dear Sir, In their letter Mühlhauser et al. [1] suspect that the reduced
mortality rate achieved in intensively insulin-treated Type II diabetic patients
after myocardial infarction compared with a conventionally treated Type II ... Cited by 16 - Related articles - BL Direct - All 7 versions
